IMVT NASDAQ Week ended 24 Jul 2026

Weekly Investor Report

Immunovant Inc · Healthcare · Biotechnology

Open interactive chart View report data Download investor PDF
Latest close 39.41 USD
-2.1% latest week
Weekly setup

Constructive, but selective

The weekly trend is active. Price is 32.8% above the Trend Line and sits at 93.2% of its 52-week range. The latest completed week returned -2.1%, after a 1.4% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 54/100 conviction, while the latest news-sentiment score is 51/100. Near-term considerations: price is close to its 52-week high; volume confirmation is below normal; earnings are due in 11d.

Setup score 67 out of 100
Latest Close 39.41 USD 24 Jul 2026
1W Return -2.1% latest completed week
4W Return 1.4% short-term follow-through
12W Return 45.3% quarterly tape
Trend Breadth 80.8% 42 of 52 weeks active
Volume Ratio 0.5x vs 13-week average
What is working
  • The trend backdrop is active with a 42-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • 5 reversal markers appear in the recent smart-money tape.
What to watch next
  • Price is close to its 52-week high; watch for continuation or exhaustion.
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -2.1% Latest completed week; four-week move 1.4%. Indicator stack 89/74 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Volatility 54/100 conviction; expected move 14.5%. News sentiment 51/100 58 relevant articles in the latest sentiment read. Event risk 11d Next report is scheduled for 10 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 32.8% above the Trend Line and sits at 93.2% of its 52-week range. The latest completed week returned -2.1%, after a 1.4% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.5x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.9612-week average 0.71

12-week confirmation

Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.96Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers55 reversal markers

No recent accumulation markers. 5 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 1.4% over four weeks, 45.3% over 12 weeks, and 132.5% over one year. The current trend has remained active for 42 consecutive weeks.

Performance by holding period

1W-2.1%
4W1.4%
12W45.3%
26W51.5%
52W132.5%
Active trend streak42 weeks
Active weeks in one year42
Trend breadth80.8%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure1.26Latest activity-pressure read.
Pressure change21.1%Four-week change in activity pressure.
Leadership44.27Latest relative-leadership reading.
RS change-0.8%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 64% Model confidence 61%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength57/100Blend of value, momentum, and quality. Underlying universe rank 44; rank 1 is best.
Value52/100Relative valuation strength. Underlying universe rank 49; rank 1 is best.
Quality51/100Profitability and accounting quality. Underlying universe rank 50; rank 1 is best.
Momentum53/100Medium-term price momentum. Underlying universe rank 48; rank 1 is best.
Growth53/100Revenue and earnings growth. Underlying universe rank 48; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-5.7%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
2/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-6.7%
Net share repurchases relative to market value.
Shareholder yield
-6.7%
Dividend yield plus net buyback yield.
Net debt / EBITDA
1.8x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

IMVT shows volatility options pressure with a 54/100 conviction score, put-call volume ratio of 0.11, expected move of 14.5%, and Sharemaestro trend signal active.

Conviction54/100
Expected move14.5%
Put/call volume0.11
Pressure90
Speculation5
Volatility93
Trend agreement20
Open options detail
Insider activity2 / 18

2 acquisitions and 18 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment51/100

Weighted news tone is neutral across 58 relevant articles.

12 positive · 40 neutral · 6 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings11dNext report is scheduled for 10 Aug 2026; event risk rises as the date approaches.
Options expected move14.5%Nearest-chain priced movement where available.
52-week drawdown-4.4%Distance below the 52-week high.
13-week volatility8.0%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher13 of 2612 weeks finished lower.
Best week+24.2%Week of 22 May.
Worst week-8.4%Week of 13 Mar.
Latest week-2.1%Week of 24 Jul.

Shape of recent returns

Strong gains9
Modest gains4
Flat weeks1
Modest losses6
Sharp losses6
Recent vol8.0%13-week weekly-return volatility.
Base vol8.0%52-week weekly-return volatility.
Up/down split27/24Count of positive and negative weeks in the 52-week window.
Average skew7.2% / -3.9%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape66/100

Trend, activity pressure, participation, and risk combine to a 66/100 tape read.

 Indicator analysis83/100

Latest 12-week confirmation: trend 12/12, activity pressure 12/12, relative leadership 12/12.

Activity pressure 0.96; 5 reversal markers Factors52/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 84; Small Cap Core rank 53 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options42/100

IMVT shows volatility options pressure with a 54/100 conviction score, put-call volume ratio of 0.11, expected move of 14.5%, and Sharemaestro trend signal active.

Volatility · Volatility expansion watch · Expected move 14.5% Sentiment51/100

Weighted news tone is neutral across 58 relevant articles.

Immunovant Insider Sold Shares Worth $263,015, According to a Recent SEC Filing Insiders2 / 18

2 acquisitions and 18 disposals in the latest 180-day insider tape.

 Earnings11d

Next report is scheduled for 10 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 202639.41 USD-2.1%29.68 USD26.60 USD1.2644.274.3MOn
17 Jul 202640.26 USD1.4%29.24 USD26.49 USD1.3946.984.2MOn
10 Jul 202639.71 USD2.4%28.78 USD26.37 USD1.3240.726.6MOn
3 Jul 202638.79 USD-0.2%28.34 USD26.25 USD1.1941.494.6MOn
26 Jun 202638.85 USD9.9%27.81 USD26.12 USD1.0444.6511.7MOn
19 Jun 202635.34 USD5.1%27.32 USD26.00 USD0.8927.308.0MOn
12 Jun 202633.62 USD8.1%26.89 USD25.90 USD1.0125.486.5MOn
5 Jun 202631.11 USD-6.6%26.57 USD25.81 USD0.7819.837.6MOn
29 May 202633.30 USD-2.5%26.31 USD25.75 USD0.7023.297.5MOn
22 May 202634.15 USD24.2%26.02 USD25.67 USD0.4831.2228.4MOn
15 May 202627.49 USD-5.0%25.51 USD25.58 USD0.168.016.0MOn
8 May 202628.94 USD6.7%25.18 USD25.54 USD0.3514.016.9MOn
1 May 202627.12 USD-5.1%24.78 USD25.47 USD0.0613.448.0MOn
24 Apr 202628.58 USD-2.5%24.44 USD25.42 USD-0.2021.917.2MOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.